桂林莱茵生物科技股份有限公司 2020 年年度报告全文 桂林莱茵生物科技股份有限公司 2020 年年度报告 2021 年 03 月 1 桂林莱茵生物科技股份有限公司 2020 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人秦本军、主管会计工作负责人郑辉及会计机构负责人(会计主管 人员)张为鹏声明：保证本年度报告中财务报告的真实、准确、完整。 年度报告中涉及公司未来计划等前瞻性的陈述，能否实现取决于市场状况 变化等多种因素，存在不确定性，并不代表公司对未来年度的盈利预测，也不 构成公司对投资者的实质承诺，投资者及相关人士应对此保持足够的风险认识， 并且应当理解计划、预测与承诺之间的差异。敬请投资者注意投资风险。 本公司敬请广大投资者认真阅读本年度报告全文，并特别注意公司存在的 政策风险、宏观经济风险、行业风险、原材料采购风险、汇率变动风险等，详 细内容见本年度报告"第四节 经营情况讨论与分析"之"九、公司未来发展的展 望"中阐述的公司可能面对的风险因素 ...

桂林莱茵生物科技股份有限公司 2020 年第三季度报告全文 桂林莱茵生物科技股份有限公司 2020 年第三季度报告 2020 年 10 月 1 桂林莱茵生物科技股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人秦本军、主管会计工作负责人郑辉及会计机构负责人(会计主管 人员)张为鹏声明：保证季度报告中财务报表的真实、准确、完整。 2 桂林莱茵生物科技股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 2,679,415,663.64 | 2,599,695,710.03 | | 3.07% | | 归属于上市公司股东的净资产（元） | 1, ...

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 280,652,409.37, representing a 7.23% increase compared to CNY 261,726,545.26 in the same period last year[18]. - The net profit attributable to shareholders of the listed company decreased by 8.93% to CNY 53,840,422.69 from CNY 59,122,631.25 year-on-year[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 21.39% to CNY 30,765,647.17 compared to CNY 39,134,659.46 in the previous year[18]. - The operating profit for the same period was CNY 62,433,629.86, a decrease of 8.12% year-on-year[48]. - The plant extraction business generated revenue of CNY 245,221,000, accounting for 87.38% of total revenue, with a year-on-year growth of 18.66%[48]. - The BT project contributed CNY 33,190,900 in revenue, representing 11.83% of total revenue, a decrease of 31.81% year-on-year[48]. - The gross profit margin for the main manufacturing business was 28.75%, with a revenue increase of 18.66% and a cost increase of 18.10% compared to the previous year[63]. - The company reported a net profit of 470.36 million yuan for the current period, which is a decrease of 28.26 million yuan compared to the previous period[190]. Cash Flow and Liquidity - The net cash flow from operating activities significantly improved to CNY 126,398,693.12, a 249.42% increase from a negative cash flow of CNY 84,593,334.80 in the same period last year[18]. - The company's cash and cash equivalents increased by 97.65% compared to the beginning of the period, primarily due to significant sales collections and new bank loans[33]. - The cash flow from operating activities saw a significant increase of 249.43%, reaching $126.40 million, primarily due to increased sales collections in the plant extraction business[61]. - The company reported a decrease in financing cash flow by 68.23%, totaling $141.99 million, mainly due to increased bank loans and the absence of funds raised from a share placement in the previous year[61]. - The total cash inflow from financing activities was ¥313,200,000.00, while the cash outflow was ¥217,038,304.80, resulting in a net cash flow of ¥96,161,695.20 from financing activities[185]. Assets and Liabilities - The total assets of the company increased by 4.39% to CNY 2,713,707,259.28 from CNY 2,599,695,710.03 at the end of the previous year[18]. - Total liabilities rose to CNY 929,151,781.70 from CNY 842,110,387.84, which is an increase of approximately 10.3%[166]. - The company's total assets at the end of the reporting period were 5,509.00 million yuan, reflecting an increase from 5,072.00 million yuan in the previous period[191]. - The company’s total liabilities at the end of the reporting period were 3,287.00 million yuan, which is an increase from 3,000.00 million yuan in the previous period[191]. Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares[5]. - Major shareholder Mr. Yao Xinde reduced his holdings by 10,306,676 shares, representing 1.823% of the company's total equity, leaving him with a 6.080% stake[138]. - The top shareholder, Qin Benjun, holds 18.74% of the shares, with a total of 26,479,877 shares pledged[146]. - The company did not experience any changes in its controlling shareholder or actual controller during the reporting period[148]. Research and Development - The company has established multiple R&D platforms, including a "Postdoctoral Research Station" and a "National Tropical Fruit Processing Technology R&D Center" to enhance its technological capabilities[37]. - The company holds 58 national invention patents and has mastered nearly 300 core technologies for natural component extraction[38]. - The company has allocated 30,861.00 million yuan for research and development in the current period, reflecting a commitment to innovation[190]. Market Strategy and Expansion - The company aims to expand its domestic marketing channels while leveraging its brand reputation to improve operational performance[31]. - The company has established sales centers in Shanghai, Los Angeles, and Savona, Italy, to enhance its global marketing strategy[30]. - The company is actively pursuing partnerships with well-known global brands, including Danone and Nestlé, to expand its market presence[50]. - The company is focusing on developing new products and enhancing strategic customer relationships to ensure sustained revenue growth in the plant extraction business[97]. Environmental and Social Responsibility - The company donated 14,760 seedlings of monk fruit and 40 tons of organic fertilizer valued at 99,040 RMB to impoverished farmers in several villages to support their spring farming efforts[137]. - The company has not reported any major environmental issues and is not classified as a key pollutant unit by environmental protection authorities[136]. Legal and Compliance - There are no significant litigation or arbitration matters reported during the period, reflecting a stable legal environment for the company[111]. - The company has not engaged in any related party transactions during the reporting period, indicating a focus on independent operations[117]. Future Outlook - The company plans to continue expanding its market presence and invest in new product development to drive future growth[190]. - The company aims to enhance its operational efficiency and explore potential mergers and acquisitions to strengthen its market position[190].

桂林莱茵生物科技股份有限公司 2020 年第一季度报告全文 桂林莱茵生物科技股份有限公司 2020 年第一季度报告 2020 年 04 月 1 桂林莱茵生物科技股份有限公司 2020 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人秦本军、主管会计工作负责人郑辉及会计机构负责人(会计主管 人员)张为鹏声明：保证季度报告中财务报表的真实、准确、完整。 一、主要会计数据和财务指标 2 公司是否需追溯调整或重述以前年度会计数据 桂林莱茵生物科技股份有限公司 2020 年第一季度报告全文 第二节 公司基本情况 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 116,978,083.20 | 104,485,780.72 | 11.96% | | 归属于上市公司股东的净利润（元） | 16,267,902.17 | 15,973,4 ...

桂林莱茵生物科技股份有限公司 2019 年度报告全文 桂林莱茵生物科技股份有限公司 2019 年年度报告 2020 年 04 月 1 桂林莱茵生物科技股份有限公司 2019 年度报告全文 第一节重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人秦本军、主管会计工作负责人郑辉及会计机构负责人(会计主管 人员)张为鹏声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及公司未来计划等前瞻性陈述，公司声明该计划不构成公司对 投资者的实质承诺，请投资者及相关人士对此保持足够的风险认识，理解计划、 预测与承诺之间的差异。 本公司敬请广大投资者认真阅读本年度报告全文，并特别注意公司存在的 政策风险、宏观经济风险、市场风险、管理风险、原材料采购风险、汇率变动 风险等，详细内容见本年度报告"第四节 经营情况讨论与分析"之"九、公司未 来发展的展望"中阐述的公司可能面对的风险因素。 公司经本次董事会审议通过的利润分配预案为：以 565,214, ...

桂林莱茵生物科技股份有限公司 2019 年第一季度报告全文 桂林莱茵生物科技股份有限公司 2019 年第一季度报告 （更新后） 2019 年 04 月 1 桂林莱茵生物科技股份有限公司 2019 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人秦本军、主管会计工作负责人郑辉及会计机构负责人(会计主管 人员)张为鹏声明：保证季度报告中财务报表的真实、准确、完整。 2 桂林莱茵生物科技股份有限公司 2019 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 104,485,780.72 | 111,482,325.48 | -6.28% | | 归属于上市公司股东的净利润（元） | 15,973,409 ...

Financial Performance - Operating revenue for the reporting period was ¥128,918,159.05, down 13.07% compared to the same period last year[7]. - Net profit attributable to shareholders of the listed company was ¥16,627,412.48, a significant increase of 219.02% year-on-year[7]. - Basic earnings per share were ¥0.03, representing a 200.00% increase compared to the same period last year[7]. - The company reported a comprehensive income of CNY 18,489,957.53 for Q3 2019, compared to CNY 7,765,957.70 in Q3 2018, reflecting improved overall performance[43]. - Net profit for Q3 2019 reached CNY 16,627,390.66, representing a significant increase of 219.56% compared to CNY 5,212,094.61 in Q3 2018[42]. - The company reported a net profit of ¥75,632,221.93 for the year-to-date period, slightly down from ¥77,472,042.49, a decrease of 2.4%[49]. - Basic earnings per share for Q3 2019 were ¥0.15, compared to ¥0.18 in the same period last year[50]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥2,594,568,025.50, an increase of 22.27% compared to the end of the previous year[7]. - The company's total liabilities decreased to CNY 854,028,273.51 from CNY 1,008,216,346.50, a reduction of approximately 15.3%[33]. - The total equity attributable to shareholders increased to CNY 1,740,739,679.99 from CNY 1,113,665,614.29, reflecting a growth of about 56.2%[34]. - The company's total liabilities amounted to CNY 582,117,640.07, a decrease from CNY 666,135,812.31 in the previous year[39]. - Total current liabilities decreased to CNY 699,562,706.47 from CNY 878,560,189.08, a reduction of about 20.4%[33]. - The total assets of the company reached CNY 2,174,175,327.46, an increase from CNY 1,650,979,323.23 in the previous year, showcasing growth in asset base[39]. Cash Flow - The net cash flow from operating activities was ¥6,609,637.12, a decrease of 77.42% compared to the previous year[7]. - The net cash flow from financing activities increased by 507.55% to approximately CNY 440.16 million, primarily due to funds received from the rights issue[16]. - Cash inflow from financing activities totaled 747,234,724.98, significantly higher than 334,733,333.89 in the previous period, indicating strong financing activity[58]. - The net cash flow from operating activities was -26,712,237.60 CNY, compared to -10,241,043.29 CNY in the previous year, indicating a decline in operational cash generation[61]. Shareholder Information - The total number of shareholders at the end of the reporting period was 59,071[11]. - The top shareholder, Qin Benjun, holds 18.74% of the shares, with 105,919,507 shares pledged[11]. Investment Activities - The company plans to invest USD 58.18 million in the construction of an industrial hemp extraction and application project in the United States[18]. - The company has established a wholly-owned subsidiary in the U.S. for the industrial hemp project, which is progressing according to the contract timeline[19]. - The company reported a net loss in investment activities of -19,065,830.63 CNY, an improvement from -71,750,964.61 CNY in the previous year[61]. Financial Adjustments - The company adjusted its financial statements in accordance with new financial instrument standards, impacting the classification of certain assets[65]. - The adjustment of "available-for-sale financial assets" to "other non-current financial assets" was made according to new financial instrument standards[69].

桂林莱茵生物科技股份有限公司 2019 年半年度报告全文 桂林莱茵生物科技股份有限公司 2019 年半年度报告 （更新后） 2019 年 08 月 1 桂林莱茵生物科技股份有限公司 2019 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人秦本军、主管会计工作负责人郑辉及会计机构负责人(会计主管 人员)张为鹏声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及公司未来计划等前瞻性陈述，公司声明该计划不构成公司对 投资者的实质承诺，请投资者及相关人士对此保持足够的风险认识，理解计划、 预测与承诺之间的差异。 本公司敬请广大投资者认真阅读半年度报告全文，并特别注意公司存在的 政策风险、宏观经济风险、市场风险、管理风险、原材料采购风险、汇率变动 风险等，详细内容见本报告"第四节 经营情况讨论与分析"之"十、公司面临 的风险和应对措施"中阐述的公司可能面对的风险因素。 公司计划不派发现金红利，不送红 ...

桂林莱茵生物科技股份有限公司 2019 年第三季度报告全文 桂林莱茵生物科技股份有限公司 2019 年第三季度报告 2019 年 10 月 1 桂林莱茵生物科技股份有限公司 2019 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人秦本军、主管会计工作负责人郑辉及会计机构负责人(会计主管 人员)张为鹏声明：保证季度报告中财务报表的真实、准确、完整。 2 桂林莱茵生物科技股份有限公司 2019 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 2,451,300,694.19 | | 2,122,029,854.59 | 15.52% | | 归属于上市公司股东的净资产 | 1,61 ...

桂林莱茵生物科技股份有限公司 2019 年半年度报告全文 桂林莱茵生物科技股份有限公司 2019 年半年度报告 2019 年 08 月 1 桂林莱茵生物科技股份有限公司 2019 年半年度报告全文 本公司敬请广大投资者认真阅读半年度报告全文，并特别注意公司存在的 政策风险、宏观经济风险、市场风险、管理风险、原材料采购风险、汇率变动 风险等，详细内容见本报告"第四节 经营情况讨论与分析"之"十、公司面临 的风险和应对措施"中阐述的公司可能面对的风险因素。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | | | | 第一节 | 重要提示、目录和释义 | 2 | | --- | --- | --- | | 第二节 | 公司简介和主要财务指标 | 6 | | 第三节 | 公司业务概要 | 9 | | 第四节 | 经营情况讨论与分析 | 13 | | 第五节 | 重要事项 | 23 | | 第六节 | 股份变动及股东情况 | 32 | | 第七节 | 优先股相关情况 | 35 | | 第八节 | 董事、监事、高级管理人员情况 | 36 | | 第九节 | 公司债相关情况 | 37 | | 第十节 | 财 ...